201 results about "Osteoporosis prevention" patented technology

The present invention relates generally to functional sweetener compositions comprising non-caloric or low-caloric high-potency sweeteners and methods for making and using them. In particular, the present invention relates to different functional sweetener compositions comprising at least one non-caloric or low-caloric natural and / or synthetic high-potency sweetener, at least one sweet taste improving composition, and at least one functional ingredient, such as an agent for the treatment and / or prevention of osteoporosis. The present invention also relates to functional sweetener compositions and methods that can improve the tastes of non-caloric or low-caloric natural and / or synthetic high-potency sweeteners by imparting a more sugar-like taste or characteristic. In particular, the functional sweetener compositions and methods provide a more sugar-like temporal profile, including sweetness onset and sweetness linger, and / or a more sugar-like flavor profile.

A method comprising orally administering to a human or other mammal a pharmaceutical composition comprising from about 65% to about 110% of the cumulative effective dose of risedronate or a pharmaceutically acceptable acid, salt, ester, solvate, or polymorph thereof according to a continuous dosing schedule of one, two, or three consecutive days per month is useful for treating or preventing osteoporosis and other bone metabolic disorders.

Disclosed are nutritional compositions and methods of using the compositions for treating or preventing osteoporosis. The compositions comprise (A) those dried fruit solids that inherently comprise flavonoids, hydroxycinnamic acids, and a fiber component of which at least about 20% by weight is soluble fiber, and (B) a soluble, indigestible oligosaccharide in addition to any soluble fiber inherently in the dried fruit solids. The dried fruit solids may also be characterized as those selected from dried plum, dried grape, dried date, or dried fig. The combination of dried fruit solids (e.g., dried plum solids) and soluble indigestible oligosaccharides (e.g., fructooligosaccharides) have been found to be surprisingly more effective in affecting bone mineral density than either component when used alone, thus allowing for reduced concentrations of such ingredients in a nutritional product form such as a beverage or solid nutritional bar.

Estrogenic compositions comprising calycosin and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

The invention discloses liquid-lowering health cookie. The liquid-lowering health cookie is made with, by weigh, 100-110 parts of flour, 40-50 parts of natto, 20-30 parts of mung bean powder, 1-2 parts of lotus leaf, 1-3 parts of Kuding, 2-3 parts of pubescent holly root, 1-2 parts of suberect spatholobus stem, 15-20 parts of broccoli, 10-14 parts of bamboo shoot, 8-12 parts of Chinese Mesona herb, 12-15 parts of wax apple, 20-30 parts of codfish, 5-8 parts of salt, 1-2 parts of cookie additive, and the proper amount of water. The natto added to the liquid-lowering health cookie is rich in protein, cellulose, calcium, iron and the like, and has the effects of thrombolysis, tumor suppression, blood pressure lowering, blood lipid lowering, oxidation resistance, osteoporosis prevention, blood clotting promotion and the like. The wax apple is a fine fruit for treating various diseases, has sweet taste and neutral nature, and has the effects of moistening lung, suppressing cough, eliminating phlegm, cooling blood, and astringing. The Chinese Mesona herb has the effects of clearing summer heat and cooling to excrete water, and has good therapeutic effect on hypertension, kidney diseases, diabetes, joint muscular pain and the like. The Kuding has the effects of clearing summer heat, improving eyesight and promoting intelligence, helping produce saliva and slake thirst, lowering blood lipid, preventing cancer and senescence, invigorating blood vessels and the like.

Estrogenic extracts of Asparagus conchinchinensis (Lour.) Merr of the Liliaceae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

The present invention is related to Nox4 inhibitors, pharmaceutical composition thereof and to their use for the treatment and / or prevention of osteoporosis or an osteoclastogenesis dysfunction, in particular osteoporotic and pre-osteoporotic osteoclastogenesis dysfunction.

The present invention relates to novel chain-fluorinated alkanoic acid derivatives thereof, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and / or αvβ5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

The invention provides a non-invasive detection kit for detecting susceptible genes of women osteoporosis. The kit comprises five osteoporosis single nucleotide polymorphism genotype specific primers, a DNA sequencing primer, a polymerase chain reaction (PCR) reaction component, a PCR product purification component, a DNA sequencing reaction component and the like, wherein the five osteoporosis single nucleotide polymorphism genotype specific primers are used for detecting G-174C on an IL-6 gene, BsmI and TaqI on a VDR gene, G-308A on a TNF-a and Lys3Asn on an OPG gene. The kit can screen out high-risk women group susceptible to osteoporosis by detecting the genotypes of the five osteoporosis single nucleotide polymorphisms closely related to osteoporosis, can evaluate the risk level susceptible to osteoporosis from gene level according to the gene detection result of every checked person and can guide menopausal women to effectively prevent osteoporosis.

The present invention relates to an application of iridoid in the preparation of anti-osteoporosis medicines, which belongs to the medicines technical field. The invention provides an application of iridoid which is shown in a general formula I in the preparation of medicines used for treating and / or preventing osteoporosis. Experiments found that ALP activity in UMR106 cells is taken as guidance for tracing and separating an extract of iridoid possessing general formula I, the extract and each separated component are researched from the aspects of osteoblast propagation and antioxidation activity, the iridoid possessing the general formula I has the effects of substantially promoting alkaline phosphatase activity and osteoblast differentiation, so that the iridoid has anti-osteoporosis effect and can be used for preparing the medicines used for treating or preventing osteoporosis. The component of specnuezhenide and a compound G13 possesses the effects of substantially promoting the alkaline phosphatase activity and osteoblast differentiation, and the specnuezhenide has effects for obviously promoting UMR-106 cell proliferation, a better effect is obtained when the specnuezhenide is used for anti-osteoporosis effect.

A non-toxic biologically active compound is provided having the following general formula (I): wherein n is an integer from 1 to 14, preferably from 2 to 4, and R is an organic moiety, preferably a group different from but structurally substantially similar to 2-methyl naphthoquinone, or a group P—C(R1)—P, where each P stands for a—PO(OH)2 group and R1 is a (poly)isoprenyl group, hydroxy, halogen (preferably chloro or bromo), or hydrogen, or a pharmaceutically acceptable derivative thereof. These compounds are useful for the treatment or prevention of certain disorders in a mammal, especially a human being, for example postmenopausal loss of bone in women, juvenile or senile osteoporosis in men and women, cardiovascular calcification and other ectopic calcifications.

The invention of this application relates to compositions and methods for the treatment and / or prevention of osteoporosis; improving and / or enhancing bone formation; and prevention and / or reducing bone mineral density loss. More particularly, the invention relates to a composition comprising vitamin K, in any form and betacryptoxanthin. A further aspect of this invention is a composition comprising vitamin K, in any form, betacryptoxanthin, and / or vitamin D and / or calcium.

The present invention relates to methods and materials used to express the HBM protein in animal cells and transgenic animals. The present invention also relates to transgenic animals expressing the high bone mass gene, the corresponding wild-type gene, and mutants thereof. The invention provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.

The present invention relates to the use of myo-inositol hexaphosphate or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or treatment of a disease associated with the dissolution of crystals of calcium salts, in particular osteoporosis. These compounds may be utilized in the manufacture of functional foods, dietetic supplements, vitamin supplements, nutritional supplements, food supplements, or phytotherapeutic products having properties of inhibition of dissolution of crystals of calcium salts.

The invention relates to application of collagen chelate in the preparation of medicament or food for enhancing bone quality. The medicament or food can enhance bone strength, can enhance bone strength and bone density at the same time and can be used for curing and / or preventing osteoporosis. The collagen chelate is a metalloprotein conjugate; compared with calcium carbonate (CaCO3) with the same calcium concentration, the collagen chelate can enhance the bone density by 4.4 percent and enhance the bone strength by 9.9 percent; and compared with a mixture of collagen and calcium carbonate (CaCO3) with the same concentration of collagen and calcium carbonate, the collagen chelate has a more obvious effect.

A method is described for the treatment of bone disease by oral dosing of a patient with an inhibitor(s) of pro-inflammatory Cytokines admixed in a pharmaceutically acceptable carrier with calcium / phosphate / magnesium / zinc or strontium salt compound ion—a hydroxyapatite matrix.

A method and compositions for regulating bone density and / or circulating lipid levels in a subject based on the combined administration of at least one isoflavone or functional derivative, equivalent or analogue thereof and at least one lipid regulating drug. The method and compositions are applicable to the beneficial alteration of blood lipoprotein levels, the improvement of vascular compliance, the decrease in the propensity of thrombogenic events, the reduction in the risk of vascular disease, coronary heart disease, and arteriosclerosis, and to the treatment or prevention of osteoporosis.

Glycine phosphate (phosphoglycine) and glycine citrate (citroglycine) are used in solubilizing carbonate salts of calcium and optionally zinc in water. Stoichiometric proportions of these ingredients when added to water cause an effervescent reaction that results in an aqueous solution containing completely solubilized and bioavailable calcium phosphate (hydroxyapatite), calcium hydrogen citrate, glycine and optionally, zinc citrate. The aqueous solution of this invention, after addition of suitable flavor(s), sweetener(s), acidulent(s), other nutritional and / or herbal ingredients can be added to the aqueous solvent. The resultant solvent provides a clear aqueous beverage including completely absorbable bone minerals for maintaining bone density and strength and to prevent osteoporosis. The beverage of the present invention can be used as a substitute for plain bottled water, sodas, and the like, and as a substitute for people who are allergic to milk.

The present invention provides a method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivative or its salt, and bisphosphonate for the purpose of using simultaneously, separately, or sequentially as active ingredients. As a prophylactic or therapeutic composition for osteoporosis, the combination treatment of the benzamidine derivative and the bisphosphonate compound exhibits excellent inhibitory effect on osteoclast differentiation than the total effect of each individual treatment, thereby being used for the prevention or treatment of osteoporosis.

This invention relates to methods for treatment, diagnosis and prevention of bone disease and comprises methods including measurement and modulation of sympathetic tone and leptin activity. Alteration of sympathetic tone in bone disease can be accomplished by decreasing or increasing leptin synthesis, leptin receptor synthesis, leptin binding to the leptin receptor, and leptin receptor activity. Alteration of sympathetic tone in bone disease can also be accomplished in the foregoing manner, in combination with traditional sympathetic nervous system agonists and / or antagonists, such as, but not limited to, a dopamine β hydroxylase antagonist or a β adrenergic antagonist for treatment or prevention of osteoporosis.

Collagen peptide chelated mineral products, pharmaceutical formulations thereof and methods for preparing same are provided. Also provided is a method for generating the optimal size of collagen peptide for optimum mineral chelation as well as optimum biological function for supporting bone health and joint health. Also disclosed are methods of increasing bone density / preventing osteoporosis, of reducing joint pain and / or joint deterioration from osteoarthritis, degenerative joint disease, joint defect, and rheumatoid arthritis.

The present invention relates to at least one probiotic strain chosen from Lactobacillus paracasei, or at least one probiotic strain chosen from Lactobacillus paracaseiin combination with at least one probiotic strain chosen from Lactobacillus plantarum, for use in the treatment or prevention of osteoporosis or for use in increasing the absorption of at Ca2+ ions, in a mammal, preferably in a human.

The invention relates to oral pharmaceutical compositions which take the form of orally-dispersible tablets containing calcium and, optionally, vitamin D and / or fluorine together with pharmaceutically-acceptable excipients and which can be used for the treatment or prevention of osteoporosis and other diseases characterised by loss of bone mass.

The invention relates to a health care food capable of preventing osteoprosis and preparation method, which is prepared mainly from prepared rehmannia root 80-800 weight parts, root bark of tree peony 30-300 weight parts, Chinese yam 40-400 weight parts, poria cocos wolf 30-300 weight parts, alisol 30-300 weight parts, cornus officinalis 40-400 weight parts, wolfberry 50-300 parts, medicinal sodium 50-300 weight parts, vitamin A 0.015-0.075 weight part, vitamin C 10-50 weight parts, vitamin D 0.015-0.075 weight part, vitamin E 1.25-10.0 weight parts, zinc gluconate 8-17 weight parts, carotene-beta 0.015-0.075 weight part, vitamin B1 0.125-0.50 weight part, vitamin B2 0.125-0.50 weight part, vitamin B6 0.125-0.50 weight part, folic acid 0.025-0.050 weight part, and sodium selenite 0.015-0.025 weight part.

The invention discloses a processing method of corn tofu, comprising the steps of: screening soybeans and corns, soaking, washing, proportioning and soybean grinding, boiling slurry, filtering, cooling, coagulating, stirring, filling, heating and cooking, cooling and molding. Corn tofu prepared with the processing method provided in the invention are nutritious, as corn contains 7 nutrient elements, i.e. calcium, Vitamin E, glutathione, cellulose, magnesium, selenium and aliphatic acid. By determination, every 100 grams of corn can provide 300 milligrams of calcium, which is nearly equal to the amount of calcium contained in dairy products. Ordinary people know that calcium plays an important role in ensuring strong skeleton and teeth and preventing osteoporosis. Once lacking calcium, decayed teeth, osteoporosis and skeletal malacosis, child dysplasia, backache and gonalgia are likely to emerge. Taking advantage of the abundant calcium contained in corn, we can make efficient nutrition combination to tofu. In taste, the unique aroma of cooked corn seriflux is integrated with the flavor of tofu. Together with the smooth taste of tofu, the balance of nutrition and edibleness of the corn tofu of the invention are substantially enhanced.

The invention discloses an application of a mesenchymal stem cell exosome in the preparation of an osteoporosis prevention and treatment drug. The extracted human umbilical cord mesenchymal stem cellexosome is intravenously injected to improve the bone volume fraction of distal femur cancellous bones, enhance the trabecular thickness and enhance the trabecular number in order to achieve the purpose of treating osteoporosis. A new way is provided for the safe and effective treatment of osteoporosis. The extracted exosome is obtained by centrifugation, concentration and reagent extraction, anda preparation method of the exosome is simple and efficient, and can effectively maintain the activity of the exosome.

The present invention relates to a nutritional composition for infants and / or toddlers comprising a lipid component which has a lipid globules coated with phospholipids. The composition is used for increasing bone mineral content, bone mineral density, preventing osteoporosis, and / or preventing ostopenia.